0.0160
+0.0015
+(10.34%)
As of 9:12:09 AM GMT+2. Market Open.
Breakdown
TTM
7/31/2024
7/31/2023
7/31/2022
7/31/2021
Total Revenue
24.5240
26.0700
23.8990
139.4270
3.8830
Cost of Revenue
0.5740
0.6140
--
75.9470
--
Gross Profit
23.9500
25.4560
23.8990
63.4800
3.8830
Operating Expense
1,667.1550
1,260.3280
3,702.4140
5,899.8490
8,597.6440
Operating Income
-1,643.2050
-1,234.8720
-3,678.5150
-5,836.3690
-8,593.7610
Net Non Operating Interest Income Expense
-7.2060
-8.6040
-13.4380
-1.3830
--
Other Income Expense
-1,075.5010
-1,207.8310
-75.8190
-43.3200
-16.5610
Pretax Income
-2,725.9120
-2,451.3070
-3,767.7720
-5,881.0720
-8,610.3220
Net Income Common Stockholders
-2,725.9120
-2,451.3070
-3,767.7720
-5,881.0720
-8,610.3220
Diluted NI Available to Com Stockholders
-2,725.9120
-2,451.3070
-3,767.7720
-5,881.0720
-8,610.3220
Basic EPS
-0.01
-0.01
-0.02
-0.03
-0.04
Diluted EPS
-0.01
-0.01
-0.02
-0.03
-0.04
Basic Average Shares
361,746.2850
318,241.9020
240,269.6040
228,453.6360
199,964.6190
Diluted Average Shares
361,746.2850
318,241.9020
240,269.6040
228,453.6360
199,964.6190
Total Operating Income as Reported
-1,545.1040
-1,135.3580
-3,603.1350
-5,684.6830
-8,535.7830
Total Expenses
1,667.7290
1,260.9420
3,702.4140
5,975.7960
8,597.6440
Net Income from Continuing & Discontinued Operation
-2,725.9120
-2,451.3070
-3,767.7720
-5,881.0720
-8,610.3220
Normalized Income
-1,650.4110
-1,243.4760
-3,691.9530
-5,837.7520
-8,593.7610
Interest Expense
7.2060
8.6040
13.4380
1.3830
--
Net Interest Income
-7.2060
-8.6040
-13.4380
-1.3830
--
EBIT
-2,718.7060
-2,442.7030
-3,754.3340
-5,879.6890
-8,610.3220
EBITDA
-2,620.6050
-2,343.1890
-3,678.9540
-5,728.0030
-8,552.3440
Reconciled Cost of Revenue
0.5740
0.6140
--
75.9470
--
Reconciled Depreciation
98.1010
99.5140
75.3800
151.6860
57.9780
Net Income from Continuing Operation Net Minority Interest
-2,725.9120
-2,451.3070
-3,767.7720
-5,881.0720
-8,610.3220
Total Unusual Items Excluding Goodwill
-1,075.5010
-1,207.8310
-75.8190
-43.3200
-16.5610
Total Unusual Items
-1,075.5010
-1,207.8310
-75.8190
-43.3200
-16.5610
Normalized EBITDA
-1,545.1040
-1,135.3580
-3,603.1350
-5,684.6830
-8,535.7830
7/31/2021 - 10/8/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ABL.HA Abbott Laboratories
115.42
+4.74%
I25.F iRhythm Technologies, Inc.
93.50
+7.47%
NYZ.BE Novacyt SA
0.5020
-2.52%
BIOV.TA Bio-View Ltd
29.30
+2.09%
WLSI Wellstar International, Inc.
0.0000
0.00%
NEOLA.ST Neola Medical AB (publ)
2.6800
+3.88%
1BSX.MI Boston Scientific Corporation
81.20
+1.50%
7AC.F Acarix AB (publ)
0.0128
-30.81%
HEART.ST Scandinavian Real Heart AB (Publ)
13.65
+5.00%
SPEC.ST SpectraCure AB (publ)
1.7700
+1.84%